ERBB2 and breast cancer: In vitro models show that combined inhibition of MKP1 and HER2 actually leads to enhanced cell death in breast cancer cells, which is consistent with other studies showing that combined approaches targeting both HER2 and DUSP1 were more efficacious than those targeting HER2 alone [30].